Boxed warnings and contraindications: what FDA injectable labels actually say

Patients comparing Botox, Dysport, Xeomin, Jeuveau, Daxxify, and Kybella usually want to know which is "safest." The honest, label-level answer is that the botulinum toxins are more alike than they are different — they share the same boxed warning, the same core contraindications, and the same categories of serious risk. The one structural outlier in the aesthetic-injectable class is Kybella (deoxycholic acid), which carries no boxed warning at all but has its own distinctive injury profile tied to where it is injected.

An analysis of the FDA prescribing information (labels) for 10 marketed aesthetic-injectable products — seven botulinum toxins (Botox, Botox Cosmetic, Dysport, Xeomin, Jeuveau, Daxxify, Myobloc), deoxycholic acid (Kybella), and two sclerosants (Asclera, Sotradecol) — makes the pattern concrete. This article maps what those labels actually say about boxed warnings, contraindications, and warnings, what the shared skeleton means for the "which toxin is safest" question, and which questions a patient can answer from the label before they ever get to the consultation room. It is educational and does not replace individualized care.

What a boxed warning is — and why every botulinum toxin has one

A boxed warning (informally, a "black box") is the FDA's most serious form of caution in prescription labeling. It signals that the drug carries a significant risk of serious or life-threatening effects. A boxed warning is not a ban; it is the agency saying "this specific risk must be at the top of the document, not buried."

All seven botulinum toxin products in this set of labels carry the same boxed warning, headed "DISTANT SPREAD OF TOXIN EFFECT." The wording is near-identical across Botox, Dysport, Xeomin, Jeuveau, Daxxify, and Myobloc: the effects of the toxin "may spread from the area of injection to produce symptoms consistent with botulinum toxin effects," including generalized muscle weakness, drooping eyelids (ptosis), double vision (diplopia), difficulty swallowing (dysphagia), voice changes (dysphonia), difficulty breathing, and urinary incontinence — reported hours to weeks after injection, "and there have been reports of death."

That boxed warning did not always exist. It was added across the class in 2009, after an FDA safety review that began in early 2008. The agency had identified roughly 225 case reports suggestive of potential iatrogenic botulism. The most serious outcomes — including hospitalization and death — occurred predominantly in children treated for limb spasticity related to cerebral palsy, frequently at doses and for uses that were not approved at the time. The 2009 action also renamed the products with non-shared generic names (onabotulinumtoxinA, abobotulinumtoxinA, incobotulinumtoxinA, rimabotulinumtoxinB) precisely to underscore that the toxins are not interchangeable and require product-specific dosing.

The botulinum toxin that smooths a frown line is the same molecule, in mechanism, that the FDA forced to carry a death warning. The doses used cosmetically are small, and serious distant spread at cosmetic doses is rare — but the label-level architecture is the same as for therapeutic dosing, because the underlying drug is the same.

The data: who carries a boxed warning

Among the 10 aesthetic-injectable labels, the boxed-warning split is binary and tracks the mechanism exactly.

All seven botulinum toxins carry the boxed warning; none of the three non-toxin injectables do. That is the single clearest label-level difference a patient can verify without a medical degree.

What every injectable label shares: the contraindications

Below the boxed warning, the contraindications converge. Across the aesthetic injectables in this set, two contraindications recur almost universally:

• Active infection at the injection site. Every botulinum toxin and Kybella is contraindicated where there is infection at the proposed injection site. Injecting into infected skin can spread infection and worsens outcomes.
• Hypersensitivity. Every botulinum toxin and Kybella is contraindicated in patients with known hypersensitivity to the active drug or any formulation component. The botulinum toxin labels specifically warn that serious, immediate hypersensitivity reactions — including anaphylaxis, serum sickness, urticaria, soft-tissue edema, and dyspnea — have been reported, and that a fatal case of anaphylaxis has been described (in a setting where lidocaine was the diluent, so the causal agent was not conclusively established).

The labels also address pregnancy and lactation under "Use in Specific Populations." All eight cosmetic-relevant products in this set discuss pregnancy, lactation, and/or nursing. The consistent posture is that adequate human data in pregnancy are lacking and the products are not recommended during pregnancy or breastfeeding — a point patients planning treatment should raise explicitly rather than assume.

Beyond the formal contraindications, two precaution themes recur across the botulinum toxin labels and matter for real-world safety. The first is neuromuscular disorders. Patients with underlying conditions affecting the neuromuscular junction — myasthenia gravis, amyotrophic lateral sclerosis (ALS), and Lambert-Eaton syndrome are the named examples — are more sensitive to the toxin's effects and may be poor candidates. This is a precaution rather than a blanket contraindication, but a credible provider asks about it before the first injection. The second is immunogenicity. Botulinum toxins are proteins, and repeated exposure can, in some patients, trigger the formation of neutralizing antibodies that render the product less effective over time. The labels and review literature associate this risk with higher doses and more frequent dosing; a patient who notices their results shortening over years of treatment should know that antibody-mediated loss of efficacy is a recognized, if uncommon, phenomenon.

Kybella: no boxed warning, but a distinctive injury profile

Kybella is the structural outlier, and it illustrates why a boxed warning is not the whole safety story. Kybella (deoxycholic acid) is injected under the chin to dissolve submental fat. It carries no boxed warning, but its warnings and precautions read differently from the toxins' — and they are shaped by anatomy, not just chemistry.

The Kybella label calls out risks tied to its injection location: marginal mandibular nerve injury (weakness of the lower-face smile muscle, usually temporary), trouble swallowing (dysphagia) when injected close to swallowing structures, and injection-site bleeding and bruising. None of the botulinum toxins share the "marginal mandibular nerve" language, because none is injected into the submental fat pad as its approved use. The lesson is general: a product's risk profile is a product of what it is and where it goes. A toxin without a boxed warning would still be a toxin; a fat-dissolver without one still has real, location-dependent injury risk.

Units are not interchangeable — and the label says so

One of the most consequential label-level facts is also one of the easiest to overlook: botulinum toxin units do not translate between products. The 2009 generic-name changes were an FDA effort to drive this home. "100 Units" of Botox is not equivalent to "100 Units" of Dysport, Xeomin, Jeuveau, or Daxxify. The dosing tables differ, and switching products requires re-deriving the dose for that specific product — not a unit-for-unit conversion.

The marketed strengths, drawn from the labels, underline how different the vials are:

Myobloc's figures look enormous because it is a type B toxin measured on a different scale entirely. A patient who hears "units" should not compare raw numbers across products — and a provider who does is misreading the label.

What this means for the "safest toxin" question

At the label level, asking which botulinum toxin is safest is close to asking the wrong question. They share the same boxed warning, overlapping contraindications (infection, hypersensitivity), the same categories of serious risk (distant spread, hypersensitivity, swallowing and breathing difficulty), and the same pregnancy-and-lactation posture. The genuine differences between them are not in the safety skeleton — they are in onset, duration, unit dosing, and the presence or absence of accessory proteins, which affect how the body may respond immunologically over time. Those are real differences worth discussing, but they are differences within a shared safety architecture, not differences in whether a boxed warning applies.

If a patient's goal is to avoid a boxed-warning drug entirely within the injectable space, the label gives a clear answer: among the major aesthetic injectables, only the non-toxins (Kybella and the sclerosants) lack one — and each of those carries its own, mechanism- and location-specific risks that the label spells out.

What to ask, using the label

• Which specific product is being injected, and does it carry a boxed warning? A provider should be able to name the product, not just the category.
• What are the contraindications for me specifically — infection, hypersensitivity, pregnancy or breastfeeding? These are label questions with yes-or-no answers.
• For Kybella, what is the marginal-mandibular-nerve and swallowing risk for my anatomy? This is the injury profile the label flags; it should be part of the consent conversation.
• If switching from one toxin to another, has the dose been re-derived for the new product? Units are not interchangeable.
• Where in the prescribing information are the serious risks, and has the consent form I am signing actually reflected them?

The labels are public. Reading them does not make anyone a clinician, but it does make the conversation before injection more equal — and for a class where every toxin carries a warning about death, an equal conversation is exactly the point.

Sources

• FDA, Botulinum Toxin Products — 2009 safety communication requiring boxed warning on distant spread of toxin effect: https://www.fda.gov/news-events/press-announcements/fda-notifies-public-session-and-new-actions-botox-and-botox-cosmetic-labeling
• FDA prescribing information, BOTOX (onabotulinumtoxinA) — boxed warning, contraindications, warnings: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103000s5189lbl.pdf
• FDA prescribing information, DYSPORT (abobotulinumtoxinA) — boxed warning and warnings/precautions: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125274s125lbl.pdf
• DailyMed (NIH/NLM), botulinum toxin labeling and Use in Specific Populations: https://dailymed.nlm.nih.gov/dailymed/
• FDA, Drugs@FDA — approved product labeling for Botox, Dysport, Xeomin, Jeuveau, Daxxify, Myobloc, and Kybella: https://www.accessdata.fda.gov/scripts/cder/daf/
• Public Citizen petition to FDA — background on the 2009 boxed warning and case reports of iatrogenic botulism: https://www.citizen.org/article/petition-to-the-fda-to-strengthen-safety-warning-for-botox-and-related-drugs-and-remove-misleading-claims-from-botox-botox-cosmetic-labeling
• NCBI Bookshelf (StatPearls), Botulinum Toxin — contraindications, neuromuscular disorder precautions, boxed warning: https://www.ncbi.nlm.nih.gov/books/NBK557387
• US Pharmacist, Botox Applications: A Review of Risks and Benefits — potency differences and neutralizing antibody risk: https://www.uspharmacist.com/article/botox-applications-a-review-of-risks-and-benefits
• AestheticMedGuide, injectable FAERS safety analysis by brand — postmarket reporting context: https://aestheticmedguide.com/blog/injectable-safety-faers-adverse-events-by-brand